Keyphrases
Monoamine Oxidase B Inhibitors
100%
Early Parkinson's Disease
100%
Odds Ratio
87%
Confidence Interval
87%
Dopamine Agonist
87%
Levodopa
75%
Parkinson's Disease
25%
Selegiline
25%
Motor Fluctuations
25%
Disease Progression
12%
Issue 1
12%
Early Treatment
12%
Randomized Controlled Trial
12%
Non-associated
12%
Adverse Events
12%
MEDLINE
12%
Cochrane Library
12%
Embase
12%
Adverse Effects
12%
Methodological Quality
12%
Levodopa Therapy
12%
Neurology
12%
Random Effects Model
12%
Conflicting Results
12%
Cochrane Central Register of Controlled Trials
12%
Movement Disorders
12%
Conference Proceedings
12%
Add-on Therapy
12%
Symptomatic Effect
12%
Unblinding
12%
Pharmacology, Toxicology and Pharmaceutical Science
Dopamine Receptor Stimulating Agent
100%
Parkinson's Disease
100%
Monoamine Oxidase B Inhibitor
100%
Levodopa
70%
Selegiline
20%
Randomized Controlled Trial
10%
Adverse Event
10%
Disease Exacerbation
10%
Motor Dysfunction
10%
Random Effects Model
10%
Add on Therapy
10%
Neuroscience
Parkinson's Disease
100%
Dopamine Agonist
100%
Monoamine Oxidase B
100%
L-DOPA
70%
Selegiline
20%
Agonist
10%
Randomized Controlled Trial
10%
Adverse Effect
10%
Stereotypic Movement Disorder
10%
Treatment of Parkinson's Disease
10%